Navigation Links
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Date:4/19/2009

SYDNEY, April 20 /PRNewswire/ -- Australian medical research company Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers.

IST has genetically engineered an antibody drug that binds specifically to a target protein found on the surface of some blood cancer cells. Laboratory studies, using cells taken from patients with a type of blood cancer called multiple myeloma, have shown that the antibody works with the human immune system to induce death of the cancer cells. It is anticipated that the antibody will potentially reduce the number of cancerous cells in multiple myeloma patients and improve patient health and wellbeing.

IST has commenced a Phase 1 trial in patients with multiple myeloma and to date six patients have been treated at The Alfred Hospital in Melbourne under the supervision of Dr. Andrew Spencer. Results so far indicate that the antibody has no side effects and final results are expected later this year.

IST's Director of Clinical Development, Dr. Rosanne Dunn, said in order to maintain the recruitment momentum, the Company is seeking to enroll another nine multiple myeloma patients with the kappa form of the disease to be treated over the next few months.

"We are very pleased that the antibody drug is performing as expected with patients suffering no adverse effects. Although this is very rare in cancer treatment it is an indication that the antibody specifically targets cancer cells and not normal cells," she said.

IST's CEO, Mr. Alan Liddle, said multiple myeloma is a very debilitating terminal disease, with an estimated patient population of over 100,000 worldwide.

He said IST is undertaking further pre-clinical work on other blood cancers and diseases that are associated with the same target and could potentially be treated with the same antibody drug.

"If we continue to be successful in the current multiple myeloma trial, we expect to be able to move into other types of blood cancer in the coming year," Mr. Liddle said.

    For further information, please contact:

    Dr. Rosanne Dunn - +61 2 9514 4060
    Alan Liddle - +61 2 9514 7437
    Immune System Therapeutics
    www.ISTL.com.au


'/>"/>
SOURCE Immune System Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Australian Technology: Detecting Breast Cancer With Hair
2. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
3. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
4. Major deCODE-led Study Underscores Role of the Brain in Obesity
5. Isogen Launches Major New Facility to Address Global Biopharma Demand
6. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
7. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
8. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
9. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
10. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):